Top

Published in:

01-06-2010 | Original Article

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX^®) therapy in Germany

Authors: Björn Wefer, Birgit Ehlken, Jörn Bremer, Harald Burgdörfer, Burkhard Domurath, Christian Hampel, Johannes Kutzenberger, Christoph Seif, Karl D. Sievert, Karin Berger, Jürgen Pannek

Published in: World Journal of Urology | Issue 3/2010

Abstract

Purpose

To evaluate treatment outcomes and resource consumption of patients with neurogenic detrusor overactivity (NDO) before and after botulinum toxin A (Botox^®) therapy in Germany.

Methods

In a multi-center, cross-sectional, retrospective cohort study, data of patients with NDO 12 months before and after the first Botox^® therapy were analyzed.

Results

214 patients (mean age 38 ± 14.8 years, 145 male, 69 female) with NDO due to spinal cord injury (81%); myelomeningocele (14%), or Multiple Sclerosis (5%) from seven hospitals were included. Mean interval between treatments was 8 months. Following treatment, mean maximum detrusor pressure, maximum cystometric capacity and detrusor compliance improved significantly. Prior to Botox^® therapy, 68% reported urinary tract infections (UTI), 63% had incontinence episodes, and 58% used incontinence aids. These numbers decreased significantly (p < 0.05) after treatment to 28, 33, and 28%, respectively. In patients using incontinence aids, mean costs per patient decreased from €2 to €1 per day, whereas the mean cost of drugs to treat UTIs per patient decreased from €163 to €80 per year, respectively.

Conclusion

This is the first study demonstrating the clinical usefulness of Botox^® therapy in clinical practice. Successful treatment resulted in lower costs for NDO associated morbidity due to less need for incontinence aids and UTI medication.

Webb DR, Fitzpatrick JM, O′Flynn JD (1984) A 15-year follow-up of 406 consecutive spinal cord injuries. Br J Urol 56:614–617CrossRefPubMed

Gerridzen RG, Thijssen AM, Dehoux E (1992) Risk factors for upper tract deterioration in chronic spinal cord injured patients. J Urol 147:416–418PubMed

Bruschini H, Almeida FG, Srougi M (2006) Upper and lower urinary tract evaluation of 104 patients with myelomeningocele without adequate urological management. World J Urol 24:224–228CrossRefPubMed

DasGupta R, Fowler CJ (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 63:153–166CrossRefPubMed

Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441–445CrossRefPubMed

Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83:346–351CrossRefPubMed

Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum—a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697CrossRefPubMed

Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaet K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF, Botox Detrusor Hyperreflexia Study Team (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200CrossRefPubMed

Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ (2008) Recommendations on the use of Botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol [Epub ahead of print]

10.

Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:232–236CrossRefPubMed

11.

Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P (2006) Cost-consequence analysis evaluating the use of Botulinum neurotoxin—a in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519–527CrossRefPubMed

12.

Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ (2009) EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol [Epub ahead of print]

13.

Rote Liste (2006) Rote Liste Service GmbH. Frankfurt/Main, Germany

14.

Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum—a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515CrossRefPubMed

15.

Sievert KD, Bremer J, Burgdörfer H, Domurath B, Hampel C, Kutzenberger J, Seif C, Stöhrer M, Wefer B, Pannek J (2007) Botulinumtoxin in der Therapie der neurogenen Detrusorhyperaktivität. Konsensuspapier zum Einsatz bei einer neurogenen Blasenfunktionsstörung. Urologe A 46:293–296CrossRefPubMed

16.

Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum—a toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172:240–243CrossRefPubMed

17.

Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and nerogenic detrusor overactivity to the first intradetrusor injection of botulinum—a toxin. J Urol 174:984–989CrossRefPubMed

18.

Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K, Knispel HH (2005) Botulinum—a toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48:984–990CrossRefPubMed

19.

Hinkel A, Finke W, Bötel U, Gatermann SG, Pannek J (2004) Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients. Urol Int 73:143–148CrossRefPubMed

20.

Gamè X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudiè I, De Boissezon X, Malavaud B, Marque P, Rischmann P (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53:613–618CrossRefPubMed

21.

Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG (2009) Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol 181:2181–2186CrossRefPubMed

Title: Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany
Authors: Björn Wefer
Birgit Ehlken
Jörn Bremer
Harald Burgdörfer
Burkhard Domurath
Christian Hampel
Johannes Kutzenberger
Christoph Seif
Karl D. Sievert
Karin Berger
Jürgen Pannek
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0466-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX^®) therapy in Germany

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2010

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

Insertion of double J stent as a therapeutic test in management of adults presenting with loin pain and equivocal ureteropelvic junction obstruction

Multi-modal treatment for metastatic renal cancer: the role of surgery

Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses

Clinical experience with survivin as a biomarker for urothelial bladder cancer

Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia